Summit Therapeutics (SMMT) Net Margin (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of Net Margin data on file, last reported at 8014.55% in Q3 2022.

• Quarterly Net Margin fell 651730.0% year-over-year to 8014.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 274831.82% (down 27079769.0% YoY) and the FY2022 annual result came in at 11174.75%, down 627691.0% from the prior year.
• Net Margin fell to 8014.55% in Q3 2022, from 5678.72% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 86.93% in Q4 2019 to a low of 42835.09% in Q2 2021.
• A 5-year average of 6600.8% and a median of 4988.73% in 2019 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2021 — Net Margin plunged 3384744 bps — and 2022, when it jumped 3715636 bps.
• Tracing SMMT's Net Margin over 5 years: stood at 1205.04% in 2018, then soared by 107 bps to 86.93% in 2019, then sank by 8520 bps to 7319.46% in 2020, then slumped by 48 bps to 10796.41% in 2021, then increased by 26 bps to 8014.55% in 2022.
• The last three Net Margin figures came in at 8014.55% (Q3 2022), 5678.72% (Q2 2022), and 8982.0% (Q1 2022), per Business Quant data.